Trials / Withdrawn
WithdrawnNCT03111901
Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
Low-dose Interleukin-2 and Pembrolizumab Among Patients With Metastatic Melanoma and Renal Cell Carcinoma
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- William Grosh, MD · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and disease control rate of the combination of pembrolizumab plus low-dose interleukin-2 in patients who have either advanced melanoma or renal cell cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab | Pembrolizumab solution |
| DRUG | Interleukin-2 | Interleukin-2 solution |
Timeline
- Start date
- 2018-10-29
- Primary completion
- 2023-10-01
- Completion
- 2023-10-01
- First posted
- 2017-04-13
- Last updated
- 2019-07-12
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03111901. Inclusion in this directory is not an endorsement.